{"api":"v1","generated_at":"2026-10-02T07:45:47.521Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-irae-hepatitis-59cb7d","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-irae-hepatitis-59cb7d/at/2026-10-02T05-34Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-02T05:34:29.993Z","snapshot_stamp":"2026-10-02T05-34Z","endpoint":{"slug":"api-magentlab-com-api-calc-irae-hepatitis-59cb7d","canonical_url":"https://api.magentlab.com/api/calc/irae_hepatitis","resource":"https://api.magentlab.com/api/calc/irae_hepatitis","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"ASCO 2018 (Brahmer) immune-related hepatitis grade from caller AST, ALT, and total bilirubin as folds of laboratory ULN (mg/dL only). Lab grade is the max of transaminase and bilirubin Table 2.2 bands; decompensated liver upgrades to grade 4; symptomatic compensated liver dysfunction upgrades to grade 3. ICI action: continue (0-1), hold (2), or permanently discontinue (3-4). Not a medical device, not a diagnosis, not DILI/RUCAM, not R factor, not a steroid dose; magent does not assay enzymes.","service_name":"magent","declared_category":null,"declared_tags":["irae-hepatitis","liver","checkpoint","asco","calculator"],"route_template":null,"registry_updated":"2026-09-28T14:05:02.725Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc irae hepatitis","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-02T05:34:29.993Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-02T05:34:29.993Z","calls_30d":3,"unique_payers_30d":1,"last_called_at":"2026-09-28T14:05:02.589Z"},"validation":{"latest":{"observed_at":"2026-10-01T07:38:47.875Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-01"},"uptime":[{"days":7,"observed":5,"passed":5,"ratio":1},{"days":30,"observed":5,"passed":5,"ratio":1},{"days":90,"observed":5,"passed":5,"ratio":1}],"history_90d":[{"observed_at":"2026-10-01T07:38:47.875Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T06:57:01.072Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T19:15:17.175Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T16:56:36.294Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T16:42:33.629Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["irae-hepatitis","liver","checkpoint","asco","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/irae_hepatitis","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T14:05:02.589Z","l30DaysTotalCalls":3,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/irae_hepatitis","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"alt_u_l":50,"ast_u_l":80,"alt_uln_u_l":40,"ast_uln_u_l":40,"bilirubin_mg_dl":1,"bilirubin_uln_mg_dl":1,"decompensated_liver":false,"symptomatic_liver_dysfunction":false},{"alt_u_l":50,"ast_u_l":80,"alt_uln_u_l":40,"ast_uln_u_l":40,"bilirubin_mg_dl":1,"bilirubin_uln_mg_dl":1,"decompensated_liver":false,"symptomatic_liver_dysfunction":false}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/irae_hepatitis","count":2,"items":[{"grade":1,"alt_u_l":50,"ast_u_l":80,"formula":"irae_hepatitis","citation":{"id":"brahmer-2018","doi":"10.1200/JCO.2017.77.6385","pmid":"29442540","title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","source":"J Clin Oncol. 2018;36(17):1714-1768","authors":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA"},"criteria":[{"met":false,"factor":"decompensated_liver"},{"met":false,"factor":"symptomatic_liver_dysfunction"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","alt_uln_u_l":40,"ast_uln_u_l":40,"icpi_action":"continue","bilirubin_mg_dl":1,"bilirubin_ratio":1,"formula_expression":"lab_grade = max(transaminase_grade(max(AST/AST_ULN, ALT/ALT_ULN)), bilirubin_grade(TBili/TBili_ULN)); first-match: decompensated_liver -> max(lab_grade, 4); else symptomatic_liver_dysfunction -> max(lab_grade, 3); else lab_grade. Transaminase: <1x -> 0, ULN-3x -> 1, >3-5x -> 2, >5-20x -> 3, >20x -> 4. Bilirubin: <1x -> 0, ULN-1.5x -> 1, >1.5-3x -> 2, >3-10x -> 3, >10x -> 4 (Brahmer 2018 Table 2.2). icpi_action: 0-1 continue, 2 hold, 3-4 permanently_discontinue. mg/dL bilirubin only. Not DILI/RUCAM. Not R factor. magent does not assay enzymes. Not a diagnosis. Not a steroid dose","transaminase_ratio":2,"bilirubin_uln_mg_dl":1,"decompensated_liver":false,"symptomatic_liver_dysfunction":false},{"grade":1,"alt_u_l":50,"ast_u_l":80,"formula":"irae_hepatitis","citation":{"id":"brahmer-2018","doi":"10.1200/JCO.2017.77.6385","pmid":"29442540","title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","source":"J Clin Oncol. 2018;36(17):1714-1768","authors":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA"},"criteria":[{"met":false,"factor":"decompensated_liver"},{"met":false,"factor":"symptomatic_liver_dysfunction"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","alt_uln_u_l":40,"ast_uln_u_l":40,"icpi_action":"continue","bilirubin_mg_dl":1,"bilirubin_ratio":1,"formula_expression":"lab_grade = max(transaminase_grade(max(AST/AST_ULN, ALT/ALT_ULN)), bilirubin_grade(TBili/TBili_ULN)); first-match: decompensated_liver -> max(lab_grade, 4); else symptomatic_liver_dysfunction -> max(lab_grade, 3); else lab_grade. Transaminase: <1x -> 0, ULN-3x -> 1, >3-5x -> 2, >5-20x -> 3, >20x -> 4. Bilirubin: <1x -> 0, ULN-1.5x -> 1, >1.5-3x -> 2, >3-10x -> 3, >10x -> 4 (Brahmer 2018 Table 2.2). icpi_action: 0-1 continue, 2 hold, 3-4 permanently_discontinue. mg/dL bilirubin only. Not DILI/RUCAM. Not R factor. magent does not assay enzymes. Not a diagnosis. Not a steroid dose","transaminase_ratio":2,"bilirubin_uln_mg_dl":1,"decompensated_liver":false,"symptomatic_liver_dysfunction":false}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["ast_u_l","ast_uln_u_l","alt_u_l","alt_uln_u_l","bilirubin_mg_dl","bilirubin_uln_mg_dl","decompensated_liver","symptomatic_liver_dysfunction"],"properties":{"alt_u_l":{"type":"number","description":"Alanine aminotransferase in U/L (1-10000). Used with alt_uln_u_l for the ALT fold. magent does not assay enzymes."},"ast_u_l":{"type":"number","description":"Aspartate aminotransferase in U/L (1-10000). Used with ast_uln_u_l for the AST fold. magent does not assay enzymes."},"alt_uln_u_l":{"type":"number","description":"Laboratory ALT upper limit of normal in U/L (5-200). Required; magent does not assume 40."},"ast_uln_u_l":{"type":"number","description":"Laboratory AST upper limit of normal in U/L (5-200). Required; magent does not assume 40."},"bilirubin_mg_dl":{"type":"number","description":"Total bilirubin in mg/dL (0.1-40). µmol/L is not accepted. magent does not assay bilirubin."},"bilirubin_uln_mg_dl":{"type":"number","description":"Laboratory total-bilirubin upper limit of normal in mg/dL (0.1-5). Required; magent does not assume 1.0."},"decompensated_liver":{"type":"boolean","description":"Decompensated liver (ascites, encephalopathy, coagulopathy, or coma) as assigned by the caller (Brahmer 2018). true or false. When true, grade is max(lab_grade, 4). magent does not examine the patient."},"symptomatic_liver_dysfunction":{"type":"boolean","description":"Symptomatic compensated hepatitis / liver dysfunction as assigned by the caller (Brahmer 2018). true or false. When true and decompensated_liver is false, grade is max(lab_grade, 3). magent does not examine the patient."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"ASCO 2018 (Brahmer) immune-related hepatitis grade from caller AST, ALT, and total bilirubin as folds of laboratory ULN (mg/dL only). Lab grade is the max of transaminase and bilirubin Table 2.2 bands; decompensated liver upgrades to grade 4; symptomatic compensated liver dysfunction upgrades to grade 3. ICI action: continue (0-1), hold (2), or permanently discontinue (3-4). Not a medical device, not a diagnosis, not DILI/RUCAM, not R factor, not a steroid dose; magent does not assay enzymes.","lastUpdated":"2026-09-28T14:05:02.725Z","serviceName":"magent","x402Version":2}]}}